Prophylactic antibacterial therapy for preventing urinary tract infections in spinal cord injury patients.
We conducted 202 trials in 161 male hospital patients to determine if prophylactic administration of ascorbic acid or antibacterials (trimethoprim-sulfamethoxazole, nalidixic acid, methenamine hippurate or nitrofurantoin macrocrystals) would prevent bacteriuria infections in spinal cord injury patients who had had at least 1 bout of bacteriuria. None of the drugs tested appeared to be statistically effective in the doses used in preventing bacteriuria in these patients. Moreover, sensitivities were lost to several drugs other than those used prophylactically. We conclude that use of prophylactic doses of ascorbic acid or antibacterials has not proved to be beneficial in spinal cord injury patients free of indwelling catheters.
D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001437:Bacteriuria / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008709:Methenamine / Q000627:therapeutic use; D009268:Nalidixic Acid / Q000627:therapeutic use; D009582:Nitrofurantoin / Q000627:therapeutic use; D013119:Spinal Cord Injuries / Q000150:complications*; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014546:Urinary Catheterization
D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D009268:Nalidixic Acid; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D009582:Nitrofurantoin; D014295:Trimethoprim; D008709:Methenamine; D013420:Sulfamethoxazole; D001205:Ascorbic Acid